SBIR grant will go toward in vivo zebrafish assays for drug metabolism and safety.
Phylonix Pharmaceuticals received a $1.25 million phase 2 SBIR grant from the National Institute of General Medical Sciences to develop in vivo zebrafish assays for assessing drug effects on Cytochrome (CYP) P450s. CYP profiling is required by the FDA for all new drug approvals.
The grant, “Zebrafish Cytochrome P450 Assays for Assessing Drug Metabolism and Drug Safety,” will support the Phylonix research program for assessing potential drug-drug interactions during preclinical research, according to Patricia McGrath, president and CEO at Phylonix.
“A rapid and robust whole zebrafish CYP assay, amenable to automation in multiwell plate formats, will accelerate drug metabolism and safety profiling and reduce the possibility of costly late-stage drug development failures or product market withdrawal after commercialization,” notes McGrath.
—
